Financial Times: Pharma industry’s return on R&D investment falls sharply
“The world’s 12 biggest drug companies are making a return of just 3.2 percent on their research and development spending this year — down from 10.1 percent in 2010, according to Deloitte’s annual survey of pharma R&D investment. At the same time the average cost of bringing a drug to market has soared to a record $2bn from $1.5bn in 2016 and $1.2bn in 2010, when the professional services firm launched its pharma survey…” (Cookson, 12/13).